In reply by Stagg, HR et al.
Dear Editor, 
 
We thank Nunn and Tweed for their response to our paper published in the July edition of 
The International Journal of Tuberculosis and Lung Disease.1 The authors raise a valid point 
regarding the potential difficulty of patient identification and accrual if running a trial 
comparing different treatment regimens in patients with rifampicin (RIF) monoresistant 
tuberculosis disease. The advent of Xpert MTB/RIF may also make country-specific 
estimation of the burden of non-multidrug resistant (MDR) RIF resistant disease increasingly 
difficult- a critical figure in the planning of such studies- as MDR and non-MDR RIF 
resistance is often reported as a composite value.2  
 
An up-to-date systematic review of the literature for non-RIF containing regimens utilised in 
drug sensitive patients would undoubtedly be beneficial. Indeed, this would require similar 
search terms to those employed by our original study (as drug resistance terms were not 
included);1;3 we would welcome members of the research community building upon this 
work. 
 
We also agree that a role for RIF in the treatment of RIF resistant disease cannot be ruled 
out and will likely depend upon phenotypic levels of resistance. A systematic review and 
meta-regression of trial data by Menzies et al. published in 2009 examined the influence of 
different baseline drug resistance patterns (including non-MDR isoniazid resistance, but not 
RIF resistance) and RIF duration on rates of treatment failure, relapse and acquisition of 
additional drug resistance.4 It would be informative to undertake something similar for non-
MDR RIF resistant tuberculosis using trial and observational data to evaluate the role of RIF 
in more detail. 
 
Yours faithfully, 
 
Helen R. Stagga 
Ross J. Harrisb 
Marc C. Lipmana,c 
on behalf of the authors 
 
a University College London, United Kingdom 
b Public Health England, United Kingdom 
c Royal Free London National Health Service Foundation Trust, United Kingdom 
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